The Molecular Basis of Malignant Pleural Mesothelioma

Overview

Journal Thorac Surg Clin

Publisher Elsevier

Specialties General Surgery
Pulmonary Medicine

Date 2020 Oct 5

PMID 33012428

Citations 25

Authors

Benjamin Wadowski

Assunta De Rienzo

Raphael Bueno

Affiliations

Soon will be listed here.

Abstract

Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural lining associated with asbestos exposure in greater than 80% of cases. It is characterized by molecular heterogeneity both between patients and within individual tumors. Next-generation sequencing technology and novel computational techniques have resulted in a greater understanding of the epigenetic, genetic, and transcriptomic hallmarks of MPM. This article reviews these features and discusses the implications of advances in MPM molecular biology in clinical practice.

Citing Articles

Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma.

Illini O, Benej M, Lang-Stoberl A, Fabikan H, Brcic L, Sucher F J Clin Med. 2024; 13(23).

PMID: 39685780 PMC: 11641944. DOI: 10.3390/jcm13237322.

Clinical Perspectives and Novel Preclinical Models of Malignant Pleural Mesothelioma: A Critical Review.

Ebrahimi A, Ak G, Ozel C, Izgordu H, Ghorbanpoor H, Hassan S ACS Pharmacol Transl Sci. 2024; 7(11):3299-3333.

PMID: 39539262 PMC: 11555512. DOI: 10.1021/acsptsci.4c00324.

Case report: targeted therapy of malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib.

Wu Y, Zhao Y, Yu L, Wang R, Feng W, Wu Y J Int Med Res. 2024; 52(11):3000605241287320.

PMID: 39534944 PMC: 11558720. DOI: 10.1177/03000605241287320.

Capsaicin Exerts Antitumor Activity in Mesothelioma Cells.

Andretta E, Costa A, Ventura E, Quintiliani M, Damiano S, Giordano A Nutrients. 2024; 16(21).

PMID: 39519591 PMC: 11547426. DOI: 10.3390/nu16213758.

A Case of Malignant Pleural Mesothelioma With Unknown Asbestos Exposure.

Paremuzyan A, Onwubuya E, Mathews J Cureus. 2024; 16(9):e69966.

PMID: 39445262 PMC: 11497062. DOI: 10.7759/cureus.69966.

References

Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, De Koning L . Co-occurring Mutations of Tumor Suppressor Genes, and , in Malignant Pleural Mesothelioma. Clin Cancer Res. 2016; 23(12):3191-3202. DOI: 10.1158/1078-0432.CCR-16-1971. View

Hylebos M, Van Camp G, van Meerbeeck J, Op de Beeck K . The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. J Thorac Oncol. 2016; 11(10):1615-26. DOI: 10.1016/j.jtho.2016.05.020. View

Gomez D, Rimner A, Simone 2nd C, Cho B, de Perrot M, Adjei A . The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma.... J Thorac Oncol. 2019; 14(7):1172-1183. DOI: 10.1016/j.jtho.2019.03.030. View

Galani V, Varouktsi A, Papadatos S, Mitselou A, Sainis I, Constantopoulos S . The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment. Cancer Chemother Pharmacol. 2019; 84(2):241-253. DOI: 10.1007/s00280-019-03878-3. View

Gordon G, Rockwell G, Godfrey P, Jensen R, Glickman J, Yeap B . Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2005; 11(12):4406-14. PMC: 1488818. DOI: 10.1158/1078-0432.CCR-04-2181. View

LaFave L, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A . Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015; 21(11):1344-9. PMC: 4636469. DOI: 10.1038/nm.3947. View

Carbone M, Ferris L, Baumann F, Napolitano A, Lum C, Flores E . BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012; 10:179. PMC: 3493315. DOI: 10.1186/1479-5876-10-179. View

Rihn B, Mohr S, McDowell S, Binet S, Loubinoux J, Galateau F . Differential gene expression in mesothelioma. FEBS Lett. 2000; 480(2-3):95-100. DOI: 10.1016/s0014-5793(00)01913-x. View

Gordon G, Rockwell G, Jensen R, Rheinwald J, Glickman J, Aronson J . Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005; 166(6):1827-40. PMC: 1363736. DOI: 10.1016/S0002-9440(10)62492-3. View

10.

Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K . Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006; 66(6):2970-9. DOI: 10.1158/0008-5472.CAN-05-3907. View

11.

Yap T, Aerts J, Popat S, Fennell D . Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017; 17(8):475-488. DOI: 10.1038/nrc.2017.42. View

12.

Luchini C, Veronese N, Yachida S, Cheng L, Nottegar A, Stubbs B . Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis. Genes Chromosomes Cancer. 2016; 55(10):741-9. DOI: 10.1002/gcc.22381. View

13.

Carbone M, Yang H, Pass H, Krausz T, Testa J, Gaudino G . BAP1 and cancer. Nat Rev Cancer. 2013; 13(3):153-9. PMC: 3792854. DOI: 10.1038/nrc3459. View

14.

Alley E, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B . Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18(5):623-630. DOI: 10.1016/S1470-2045(17)30169-9. View

15.

Melaiu O, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R . A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. Mutat Res. 2011; 750(2):132-140. DOI: 10.1016/j.mrrev.2011.12.003. View

16.

Christensen B, Houseman E, Godleski J, Marsit C, Longacker J, Roelofs C . Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 2009; 69(1):227-34. PMC: 2744125. DOI: 10.1158/0008-5472.CAN-08-2586. View

17.

Borczuk A, Pei J, Taub R, Levy B, Nahum O, Chen J . Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther. 2016; 17(3):328-35. PMC: 4847993. DOI: 10.1080/15384047.2016.1145850. View

18.

Vaske C, Benz S, Sanborn J, Earl D, Szeto C, Zhu J . Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010; 26(12):i237-45. PMC: 2881367. DOI: 10.1093/bioinformatics/btq182. View

19.

Vigneswaran W, Kircheva D, Ananthanarayanan V, Watson S, Arif Q, Celauro A . Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma. Ann Thorac Surg. 2016; 103(3):962-966. DOI: 10.1016/j.athoracsur.2016.08.063. View

20.

Guo R, DuBoff M, Jayakumaran G, Kris M, Ladanyi M, Robson M . Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. J Thorac Oncol. 2019; 15(4):655-660. PMC: 7526793. DOI: 10.1016/j.jtho.2019.12.111. View